{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:31:19Z","timestamp":1791192679157,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T00:00:00Z","timestamp":1458259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T00:00:00Z","timestamp":1458259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The biological basis of essential thrombocythemia (ET) patients lacking known mutations is still unknown. MicroRNAs (miRNA) regulate hematopoietic differentiation and are deregulated in several hematopoietic malignancies. However, miRNA expression in ET patients has been poorly explored. We performed miRNA profiling in platelets from 19 ET patients and 10 healthy controls. Hierarchical cluster analysis showed two well-separated clusters between patients and controls, indicating that ET platelets had a characteristic 70-miRNA signature (<jats:italic>P<\/jats:italic>&lt;0.0001), 68 of which were downregulated. According to the mutational status, three differentially expressed miRNAs, miR-15a (<jats:italic>P<\/jats:italic>=0.045), miR-150 (<jats:italic>P<\/jats:italic>=0.001) and miR-519a (<jats:italic>P<\/jats:italic>=0.036), were identified. A 40-miRNA signature was identified characterizing JAK2V617F-positive ET patients. Eight genes, whose interaction with the miRNAs could activate the JAK\/STAT pathway were identified. An inverse correlation was observed between miRNAs expression and their target genes for <jats:italic>SOCS1<\/jats:italic> and miR-221, <jats:italic>SOCS3<\/jats:italic> and miR-221, <jats:italic>SOCS3<\/jats:italic> and miR-203, and PTPN11 and miR-23a. All three miRNAs were upregulated in JAK2V617F-negative ET patients. SOCS1 and SOCS3 were validated as targets of miR-221 and miR-203, respectively. In summary, our study shows that platelets from JAK2V617F-negative ET patients harbor a specific miRNA signature that can participate in the modulation of the JAK\/STAT pathway through regulation of key genes as <jats:italic>SOCS1<\/jats:italic> and <jats:italic>SOCS3<\/jats:italic>.<\/jats:p>","DOI":"10.1038\/bcj.2016.10","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T14:22:07Z","timestamp":1458310927000},"page":"e406-e406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia"],"prefix":"10.1038","volume":"6","author":[{"given":"A","family":"Navarro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Pairet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"\u00c1lvarez-Larr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Longar\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Fern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Monz\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Besses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Bellosillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,18]]},"reference":[{"key":"BFbcj201610_CR1","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1056\/NEJMra063728","volume":"355","author":"PJ Campbell","year":"2006","unstructured":"Campbell PJ, Green AR . The myeloproliferative disorders. N Engl J Med 2006; 355: 2452\u20132466.","journal-title":"N Engl J Med"},{"key":"BFbcj201610_CR2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.5858\/2006-130-1144-ET","volume":"130","author":"S Sanchez","year":"2006","unstructured":"Sanchez S, Ewton A . Essential thrombocythemia: a review of diagnostic and pathologic features. Arch Pathol Lab Med 2006; 130: 1144.","journal-title":"Arch Pathol Lab Med"},{"key":"BFbcj201610_CR3","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779\u20131790.","journal-title":"N Engl J Med"},{"key":"BFbcj201610_CR4","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","volume":"118","author":"W Vainchenker","year":"2011","unstructured":"Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA . New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011; 118: 1723\u20131735.","journal-title":"Blood"},{"key":"BFbcj201610_CR5","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/leu.2008.229","volume":"22","author":"O Kilpivaara","year":"2008","unstructured":"Kilpivaara O, Levine R . JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 2008; 22: 1813\u20131817.","journal-title":"Leukemia"},{"key":"BFbcj201610_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1182\/asheducation-2014.1.287","volume":"2014","author":"J Nangalia","year":"2014","unstructured":"Nangalia J, Green TR . The evolving genomic landscape of myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2014; 2014: 287\u2013296.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFbcj201610_CR7","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391\u20132405.","journal-title":"N Engl J Med"},{"key":"BFbcj201610_CR8","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379\u20132390.","journal-title":"N Engl J Med"},{"key":"BFbcj201610_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel DP . MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215\u2013233.","journal-title":"Cell"},{"key":"BFbcj201610_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1126\/science.1091903","volume":"303","author":"C-Z Chen","year":"2004","unstructured":"Chen C-Z, Li L, Lodish HF, Bartel DP . MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303: 83\u201386.","journal-title":"Science"},{"key":"BFbcj201610_CR11","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/leu.2008.30","volume":"22","author":"M Fabbri","year":"2008","unstructured":"Fabbri M, Garzon R, Andreeff M, Kantarjian H, Garcia-Manero G, Calin G . MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 2008; 22: 1095\u20131105.","journal-title":"Leukemia"},{"key":"BFbcj201610_CR12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/bjh.12276","volume":"161","author":"H Zhan","year":"2013","unstructured":"Zhan H, Cardozo C, Raza A . MicroRNAs in myeloproliferative neoplasms. Br J Haematol 2013; 161: 471\u2013483.","journal-title":"Br J Haematol"},{"key":"BFbcj201610_CR13","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/sj.leu.2404649","volume":"21","author":"B Bellosillo","year":"2007","unstructured":"Bellosillo B, Martinez-Aviles L, Gimeno E, Florensa L, Longaron R, Navarro G et al. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis. Leukemia 2007; 21: 1331\u20131332.","journal-title":"Leukemia"},{"key":"BFbcj201610_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2141.2007.06755.x","volume":"139","author":"K Toyama","year":"2007","unstructured":"Toyama K, Karasawa M, Yamane A, Irisawa H, Yokohama A, Saitoh T et al. JAK2\u2010V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. Br J Haematol 2007; 139: 64\u201369.","journal-title":"Br J Haematol"},{"key":"BFbcj201610_CR15","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292\u20132302.","journal-title":"Blood"},{"key":"BFbcj201610_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-2141.2010.08430.x","volume":"152","author":"JC Hern\u00e1ndez\u2010Boluda","year":"2011","unstructured":"Hern\u00e1ndez\u2010Boluda JC, Alvarez\u2010Larr\u00e1n A, G\u00f3mez M, Angona A, Amat P, Bellosillo B et al. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol 2011; 152: 81\u201388.","journal-title":"Br J Haematol"},{"key":"BFbcj201610_CR17","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.3109\/10428194.2012.763123","volume":"54","author":"G Ferrer","year":"2013","unstructured":"Ferrer G, Navarro A, Hodgson K, Aymerich M, Pereira A, Baumann T et al. MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia. Leuk Lymphoma 2013; 54: 2016\u20132022.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201610_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/leu.2012.278","volume":"27","author":"M D\u00edaz-Bey\u00e1","year":"2012","unstructured":"D\u00edaz-Bey\u00e1 M, Navarro A, Ferrer G, Diaz T, Gel B, Camos M et al. Acute myeloid leukemia with translocation (8; 16)(p11; p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene. Leukemia 2012; 27: 595\u2013603.","journal-title":"Leukemia"},{"key":"BFbcj201610_CR19","doi-asserted-by":"publisher","first-page":"W498","DOI":"10.1093\/nar\/gks494","volume":"40","author":"IS Vlachos","year":"2012","unstructured":"Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M et al. DIANA miRPath v. 2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res 2012; 40: W498\u2013W504.","journal-title":"Nucleic Acids Res"},{"key":"BFbcj201610_CR20","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1182\/blood-2009-02-204842","volume":"114","author":"A Navarro","year":"2009","unstructured":"Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B et al. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 2009; 114: 2945\u20132951.","journal-title":"Blood"},{"key":"BFbcj201610_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1182\/blood-2008-06-165985","volume":"116","author":"M Girardot","year":"2010","unstructured":"Girardot M, Pecquet C, Boukour S, Knoops L, Ferrant A, Vainchenker W et al. miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood 2010; 116: 437\u2013445.","journal-title":"Blood"},{"key":"BFbcj201610_CR22","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1182\/blood-2012-02-411264","volume":"120","author":"X Xu","year":"2012","unstructured":"Xu X, Gnatenko DV, Ju J, Hitchcock IS, Martin DW, Zhu W et al. Systematic analysis of microRNA fingerprints in thrombocythemic platelets using integrated platforms. Blood 2012; 120: 3575\u20133585.","journal-title":"Blood"},{"key":"BFbcj201610_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.devcel.2008.03.012","volume":"14","author":"J Lu","year":"2008","unstructured":"Lu J, Guo S, Ebert BL, Zhang H, Peng X, Bosco J et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell 2008; 14: 843\u2013853.","journal-title":"Dev Cell"},{"key":"BFbcj201610_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.neo.2015.04.005","volume":"17","author":"R Moles","year":"2015","unstructured":"Moles R, Bellon M, Nicot C . STAT1: A Novel Target of miR-150 and miR-223 Is Involved in the Proliferation of HTLV-I\u2013Transformed and ATL Cells. Neoplasia 2015; 17: 449\u2013462.","journal-title":"Neoplasia"},{"key":"BFbcj201610_CR25","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc2210","volume":"7","author":"RL Levine","year":"2007","unstructured":"Levine RL, Pardanani A, Tefferi A, Gilliland DG . Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7: 673\u2013683.","journal-title":"Nat Rev Cancer"},{"key":"BFbcj201610_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O'Shea","year":"2013","unstructured":"O'Shea JJ, Holland SM, Staudt LM . JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013; 368: 161\u2013170.","journal-title":"N Engl J Med"},{"key":"BFbcj201610_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387\u2013397.","journal-title":"Cancer Cell"},{"key":"BFbcj201610_CR28","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472\u20133476.","journal-title":"Blood"},{"key":"BFbcj201610_CR29","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/ijc.23694","volume":"123","author":"L Teofili","year":"2008","unstructured":"Teofili L, Martini M, Cenci T, Guidi F, Torti L, Giona F et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer 2008; 123: 1586\u20131592.","journal-title":"Int J Cancer"},{"key":"BFbcj201610_CR30","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/jcmm.12103","volume":"17","author":"MY Zhang","year":"2013","unstructured":"Zhang MY, Fung TK, Chen FY, Chim CS . Methylation profiling of SOCS1, SOCS2, SOCS3, CISH and SHP1 in Philadelphia\u2010negative myeloproliferative neoplasm. J Cell Mol Med 2013; 17: 1282\u20131290.","journal-title":"J Cell Mol Med"},{"key":"BFbcj201610_CR31","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1136\/jclinpath-2011-200175","volume":"64","author":"S Barrio","year":"2011","unstructured":"Barrio S, Gallardo M, Albizua E, Jimenez A, Rapado I, Ayala R et al. Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation. J Clin Pathol 2011; 64: 1010\u20131013.","journal-title":"J Clin Pathol"},{"key":"BFbcj201610_CR32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/sj.leu.2404513","volume":"21","author":"E Jost","year":"2007","unstructured":"Jost E, Dahl E, Maintz C, Jousten P, Habets L, Wilop S et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR\/ABL-negative myeloproliferative disorders. Leukemia 2007; 21: 505\u2013510.","journal-title":"Leukemia"},{"key":"BFbcj201610_CR33","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.3324\/haematol.13043","volume":"93","author":"N Fourouclas","year":"2008","unstructured":"Fourouclas N, Li J, Gilby DC, Campbell PJ, Beer PA, Boyd EM et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica 2008; 93: 1635\u20131644.","journal-title":"Haematologica"},{"key":"BFbcj201610_CR34","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1177\/1947601911425832","volume":"2","author":"P Ru","year":"2011","unstructured":"Ru P, Steele R, Hsueh EC, Ray RB . Anti-miR-203 upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer 2011; 2: 720\u2013727.","journal-title":"Genes Cancer"},{"key":"BFbcj201610_CR35","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1128\/IAI.00082-11","volume":"79","author":"CE Moffatt","year":"2011","unstructured":"Moffatt CE, Lamont RJ . Porphyromonas gingivalis induction of microRNA-203 expression controls suppressor of cytokine signaling 3 in gingival epithelial cells. Infect Immun 2011; 79: 2632\u20132637.","journal-title":"Infect Immun"},{"key":"BFbcj201610_CR36","doi-asserted-by":"crossref","unstructured":"Zhou X, Liu W, Gu M, Zhou H, Zhang G . Helicobacter pylori infection causes hepatic insulin resistance by the c-Jun\/miR-203\/SOCS3 signaling pathway. J Gastroenterol 2015, 1\u201314.","DOI":"10.1007\/s00535-015-1051-6"},{"key":"BFbcj201610_CR37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.virol.2014.06.024","volume":"462","author":"G Xu","year":"2014","unstructured":"Xu G, Yang F, Ding C-L, Wang J, Zhao P, Wang W et al. MiR-221 accentuates IFN\u2019 s anti-HCV effect by downregulating SOCS1 and SOCS3. Virology 2014; 462: 343\u2013350.","journal-title":"Virology"},{"key":"BFbcj201610_CR38","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccr.2008.04.018","volume":"13","author":"MJ Bueno","year":"2008","unstructured":"Bueno MJ, de Castro IP, de Cedr\u00f3n MG, Santos J, Calin GA, Cigudosa JC et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008; 13: 496\u2013506.","journal-title":"Cancer Cell"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201610.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201610","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201610.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T09:05:55Z","timestamp":1672823155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,18]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3]]}},"alternative-id":["BFbcj201610"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2016.10","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,18]]},"assertion":[{"value":"14 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}